Great presentation that provides the complete picture and outlines the clinical catalysts ahead for this year.
We have several innovative platforms with programs combining our technologies too! Not only is that impressive in itself but the company has mapped out ways of accelerating the trial transitions to progress Ph1 trials towards Ph2 sooner rather than later.
If the company gets its pound of flesh out of our CEO (aka her valuable knowledge, experience, and networks that we are paying for), who knows what partnerships may eventuate? The tech is innovative, novel, and proving safe plus effective. M&A is very much back in favour in the biotech space with the overall sector gaining traction.
Ann: Chimeric to present at NWR Virtual Healthcare Conference, page-13
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.951M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.2¢ | 1.0¢ | $38.54K | 3.639M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 2646760 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 729690 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| CHM (ASX) Chart |